Peptide Stack · Tissue Repair · Recovery

The KLOW Stack: BPC-157, TB-500, GHK-Cu and KPV for Complete Tissue Repair

Four peptides targeting distinct healing pathways - angiogenesis, structural remodeling, collagen synthesis, and inflammation control. How the KLOW stack works, what the research says, and practical dosing protocols.

BPC-157 · Gastric Pentadecapeptide TB-500 · Thymosin Beta-4 GHK-Cu · Copper Tripeptide KPV · Anti-Inflammatory Tripeptide

Active Peptides
in Stack

Healing Pathways
Targeted

4–8

Week Typical
Cycle Length

Multi

Tissue Types
Supported

Tissue repair is not a single-step process. It involves overlapping phases of inflammation control, cell migration, structural rebuilding, and long-term remodeling. The KLOW peptide stack was designed around this reality, combining four compounds that each handle a different piece of the healing puzzle.

BPC-157 drives angiogenesis and growth factor signaling. TB-500 handles structural repair and cell migration. GHK-Cu brings collagen synthesis, stem cell recruitment, and antioxidant protection. KPV suppresses inflammatory signaling at the NF-kB level, calming the excessive inflammation that slows recovery. Together, they cover the full spectrum of what injured tissue actually needs to heal.

If the name sounds familiar but different, you might be thinking of the GLOW stack - a three-compound version that uses BPC-157, TB-500, and GHK-Cu without KPV. KLOW adds the dedicated anti-inflammatory layer that GLOW lacks, making it the more comprehensive option for injury recovery and tissue repair.

What This Guide Covers

This is an educational breakdown of the KLOW stack covering mechanisms, dosing protocols, healing timelines, safety considerations, and practical administration. It is not a recommendation to use these peptides. None of these compounds are FDA-approved for human therapeutic use. Consult a qualified healthcare provider before considering any peptide regimen.

The Four KLOW Components

Component 1

BPC-157: The Healing Signal Peptide

Full Name: Body Protection Compound-157 | Type: Synthetic gastric pentadecapeptide | Sequence: 15 amino acids derived from human gastric juice | Primary Actions: Angiogenesis, tendon-to-bone healing, GI protection, growth factor modulation

BPC-157 originates from a protective protein found in human stomach acid. It acts primarily as a signaling molecule, telling the body to ramp up its native repair processes. Research shows it accelerates healing in tendons, ligaments, muscles, and gut lining by stimulating growth factor production and forming new blood vessels at injury sites.

Component 2

TB-500: The Structural Repair Peptide

Full Name: Thymosin Beta-4 (synthetic fragment) | Type: Actin-binding peptide | Molecular Role: Cell migration, extracellular matrix remodeling | Primary Actions: Tissue remodeling, anti-inflammatory, wound closure, scar reduction

TB-500 is a synthetic version of thymosin beta-4, a naturally occurring peptide that regulates actin proteins. Actin is fundamental to how cells move and maintain their structure. By influencing actin polymerization, TB-500 increases cell mobility, promotes tissue remodeling after injury, and helps reduce excessive collagen deposition that leads to scarring.

Component 3

GHK-Cu: The Copper Peptide Complex

Full Name: Glycyl-L-Histidyl-L-Lysine:Copper(II) | Type: Copper-binding tripeptide | Sequence: Gly-His-Lys + Cu2+ | Primary Actions: Collagen/elastin synthesis, stem cell attraction, antioxidant protection, gene modulation

GHK-Cu is a naturally occurring copper-binding peptide that declines with age. It stimulates collagen and elastin production, attracts immune cells and stem cells to injury sites, and provides antioxidant protection against oxidative damage. It also modulates the expression of over 4,000 genes involved in tissue repair and regeneration.

Component 4

KPV: The Inflammation Controller

Full Name: Lys-Pro-Val (KPV) | Type: C-terminal tripeptide of alpha-melanocyte-stimulating hormone (alpha-MSH) | Sequence: 3 amino acids | Primary Actions: NF-kB suppression, IL-1 beta blockade, TNF-alpha inhibition, gut barrier support

KPV is the smallest active fragment of alpha-MSH, carrying the anti-inflammatory punch of the full hormone in just three amino acids. Unlike its parent molecule, KPV does not bind to melanocortin receptors (MC-1R) - it works through a different mechanism, directly suppressing NF-kB activation, the master switch for inflammatory gene expression. Research shows KPV blocks IL-1 beta binding to T cells and inhibits TNF-alpha production. It's absorbed via the PepT1 transporter in intestinal cells, which means it can be taken orally for gut-specific inflammation. This is the compound that makes KLOW more than just a repair stack - it actively quiets the inflammatory environment so the other three peptides can do their work more effectively.

Why KPV Makes KLOW Different From GLOW

The three-compound GLOW stack (BPC-157 + TB-500 + GHK-Cu) covers repair signaling, structural remodeling, and collagen synthesis. But excessive inflammation can slow all three processes. KPV adds a dedicated anti-inflammatory layer that the other compounds don't fully provide on their own. This is especially relevant for injuries with significant swelling, gut-related recovery, or chronic inflammatory conditions where the healing environment itself needs repair.

How the KLOW Stack Works: Synergistic Healing

Each KLOW component targets a different stage and mechanism of tissue repair. The real value of this stack is that these mechanisms overlap and reinforce each other. KPV calms the inflammatory response. BPC-157 builds blood supply to the injury. TB-500 moves repair cells into position. GHK-Cu supplies the raw materials for rebuilding.

KLOW Stack: Four-Pathway Healing Mechanism

Inflammation control · Angiogenesis · Structural remodeling · Collagen synthesis

Synergy Matrix: Who Does What

The beauty of this stack is that almost every critical healing mechanism is covered by at least two of the four peptides. That redundancy matters. If one compound underperforms in a given tissue type, another picks up the slack.

Healing Mechanism	BPC-157	TB-500	GHK-Cu	KPV
Angiogenesis	Strong	Strong	Moderate	Minimal
Collagen synthesis	Strong	Indirect	Strong	Minimal
Stem cell recruitment	Moderate	Strong	Strong	Minimal
Inflammation control	Strong	Strong	Strong	Strong
NF-kB suppression	Moderate	Minimal	Minimal	Strong
Gut barrier support	Strong	Minimal	Minimal	Strong
Antioxidant effects	Minimal	Minimal	Strong	Moderate
Nerve regeneration	Strong	Moderate	Minimal	Minimal
Scar reduction	Moderate	Strong	Strong	Minimal

Why Four Peptides Beat Three

The GLOW stack (BPC-157 + TB-500 + GHK-Cu) gives you excellent repair coverage across angiogenesis, structural remodeling, and collagen synthesis. But inflammation is more than a side effect of injury - it's an active barrier to healing when it runs unchecked. KPV adds a dedicated anti-inflammatory mechanism that works at the NF-kB level, something the other three compounds don't directly target. This is why KLOW consistently outperforms GLOW in protocols involving significant inflammation, gut involvement, or chronic conditions.

Dosing Protocols

The standard KLOW protocol reflects the most commonly cited dosing ranges in peptide research and clinical reports. Individual adjustments depend on injury type, severity, and body weight. Always work with a healthcare provider when determining your protocol.

Standard KLOW Protocol

Peptide	Dose	Frequency	Duration
BPC-157	250-500 mcg	Twice daily (AM/PM)	4-8 weeks
TB-500	2.5 mg	Twice weekly	6-8 weeks
GHK-Cu	2-4 mg	Daily	6-8 weeks
KPV	200-500 mcg	Daily	4-8 weeks

Pre-Mixed KLOW Vial Protocol (80mg)

Many vendors sell KLOW as a pre-mixed 80mg vial containing GHK-Cu (50mg), BPC-157 (10mg), TB-500 (10mg), and KPV (10mg). If you're using the pre-mixed blend:

Phase	Daily Dose (per component)	Syringe Units
Weeks 1-2 (intro)	BPC/TB/KPV: 250 mcg each, GHK-Cu: 1.25 mg	7.5 units (0.075 mL)
Weeks 3-4	BPC/TB/KPV: 500 mcg each, GHK-Cu: 2.5 mg	15 units (0.15 mL)
Weeks 5-8	BPC/TB/KPV: 750 mcg each, GHK-Cu: 3.75 mg	22.5 units (0.225 mL)
Weeks 9-12 (maintain)	BPC/TB/KPV: 500 mcg each, GHK-Cu: 2.5 mg	15 units (0.15 mL)

Reconstitute the 80mg vial with 3.0 mL bacteriostatic water for a total concentration of ~26.7 mg/mL. Inject slowly down the vial wall, swirl gently (don't shake), and refrigerate at 2-8 C after reconstitution.

Injury-Specific Modifications

Tendon and Ligament Injuries

BPC-157 at 500 mcg twice daily. TB-500 front-loaded at 5 mg twice weekly for the first two weeks, then standard dosing. Consider extending the full cycle to 10 weeks for chronic tendonopathies.

Muscle Tears and Strains

TB-500 front-loaded at 5 mg twice weekly for three weeks. GHK-Cu at 4 mg daily. Add topical GHK-Cu directly over the affected area for localized support.

Joint Inflammation

BPC-157 at 250 mcg twice daily. Consider adding KPV peptide at 200 mcg daily for extra anti-inflammatory support. Apply topical GHK-Cu to affected joints.

Post-Surgical Recovery

Full standard protocol starting 48 hours post-surgery (with physician approval). BPC-157 at 500 mcg twice daily for accelerated wound closure. GHK-Cu topical application around (not on) incision sites.

Healing Timeline: What to Expect

Recovery follows a predictable pattern, but the speed varies by injury type and individual biology. The KLOW stack supports each phase. Setting realistic expectations matters more than chasing fast results.

Phase 1: Days 1-7

Inflammation Control

The first week is about calming the acute inflammatory response. Most users notice reduced swelling and decreased pain at the injury site within 3 to 5 days. Mobility starts improving. BPC-157 and TB-500 are doing the heavy lifting here, modulating inflammatory cytokines and reducing excess fluid accumulation.

Phase 2: Weeks 1-4

Early Tissue Repair

This is where the real rebuilding begins. New blood vessels form at the injury site (thanks to BPC-157). TB-500 mobilizes repair cells. GHK-Cu ramps up collagen production. Users typically report noticeable functional improvement, decreased tenderness, and increased range of motion during this phase.

Phase 3: Weeks 4-12

Maturation and Remodeling

Tissue continues strengthening and reorganizing long after the pain subsides. Collagen fibers align properly. Scar tissue remodels into more functional tissue. This phase benefits heavily from GHK-Cu's gene modulation effects. Gradual return to full activity is appropriate here, not a rush back to peak performance.

Realistic Expectations

Healing is not linear. Some weeks show obvious progress; others feel like a plateau. Tissue remodeling continues for months after symptoms resolve. Patience and consistency with the protocol matter more than increasing doses when progress feels slow.

What the Research Actually Shows

Most KLOW research exists at the individual compound level rather than studying the four-peptide combination together. That said, the evidence for each component is substantial enough to explain why stacking them makes mechanistic sense.

BPC-157 Evidence

Preclinical Data Is Extensive

BPC-157 has been studied in over 100 animal models covering tendon, ligament, muscle, bone, and gut injuries. It consistently accelerates healing timelines by 30 to 50 percent in controlled settings. The most compelling data involves tendon-to-bone healing, where BPC-157 outperformed standard recovery in multiple rat models. Human clinical trials remain limited, which is the main gap in the evidence base.

TB-500 Evidence

Strong Mechanistic Support

Thymosin beta-4 (the parent molecule of TB-500) has been studied in human wound-healing trials and shows clear benefits for corneal repair, cardiac tissue recovery, and skin wound closure. TB-500 specifically has extensive preclinical data in equine medicine, where it has been used for decades in racehorse recovery. The translation to human tissue repair is biologically plausible given the conserved mechanisms across mammals.

GHK-Cu Evidence

Well-Characterized Compound

GHK-Cu is one of the most studied copper peptides in dermatology and wound healing. It has human data for skin repair, including randomized trials showing improved wound closure and collagen density. Its gene-modulating effects have been mapped across thousands of genes involved in tissue repair, inflammation, and aging. The topical formulation has the strongest clinical evidence; injectable protocols draw more from preclinical work.

KPV Evidence

Targeted Anti-Inflammatory Research

KPV's anti-inflammatory activity is well-documented in peer-reviewed research. A key 2008 study in Gastroenterology demonstrated that KPV is absorbed via the PepT1 transporter in intestinal epithelial cells and reduces intestinal inflammation in colitis models. Multiple studies confirm it suppresses NF-kB activation - the master inflammatory switch - independent of melanocortin receptor binding. Research in bronchial epithelial cells shows KPV suppresses inflammatory signaling in lung tissue. The compound benefits from alpha-MSH's decades of anti-inflammatory research, as KPV carries the same C-terminal activity in a more stable, smaller package. Human data is limited to the broader alpha-MSH literature, but the mechanism is clearly defined.

Evidence Gaps to Know About

No published study has tested the four-compound KLOW combination in humans. The synergy rationale comes from mechanistic reasoning, not direct clinical proof. Individual responses will vary. This stack falls into the category of "biologically plausible and well-reasoned" rather than "clinically proven as a combination."

Common Use Cases

The KLOW stack gets used across a range of injury types and recovery scenarios. Here are the applications where anecdotal reports and mechanistic fit are strongest.

Athletic Injuries

Tendon strains, muscle tears, and ligament sprains are the most common use case. Athletes report faster return-to-play timelines, particularly for hamstring, achilles, and rotator cuff injuries. The stack addresses both the acute inflammation and the longer-term structural repair these injuries require.

Post-Surgical Recovery

Users recovering from orthopedic surgery (ACL reconstruction, meniscus repair, joint replacement) report improved wound healing and faster rehabilitation milestones. The stack is typically started 48 to 72 hours after surgery with physician approval.

Chronic Joint Issues

Osteoarthritis and chronic tendonopathies respond to the anti-inflammatory and regenerative properties of the stack. These conditions often require longer cycles (8 to 12 weeks) and may benefit from maintenance dosing. Topical GHK-Cu on affected joints adds localized support.

General Recovery Optimization

Some users run shorter KLOW cycles (4 to 6 weeks) during periods of intense training or physical stress. The goal is injury prevention and accelerated recovery between training sessions rather than treating a specific injury. This is the least evidence-supported application.

Regardless of the use case, the same principles apply: source quality peptides, follow proper reconstitution and storage protocols, work with a healthcare provider, and set realistic timelines for results.

Safety Profile and Side Effects

All four KLOW components have favorable safety profiles based on available research. Most users tolerate them well at standard doses. Side effects, when they occur, tend to be mild and temporary.

Side Effect	Frequency	Severity	Management
Injection site reactions	Common	Mild	Rotate sites; use 29–31g needles
Headache	Occasional	Mild	Stay hydrated; reduce dose if persistent
Temporary fatigue	Rare	Mild	Dose in evening; ensure adequate sleep
Copper imbalance (GHK-Cu)	Rare	Mild-Moderate	Monitor zinc levels; consider zinc supplementation
Nausea	Rare	Mild	Take with food; reduce BPC-157 dose temporarily
Skin flushing (KPV)	Rare	Mild	Transient; related to alpha-MSH pathway; resolves within hours

Who Should Not Use KLOW

Individuals with copper metabolism disorders (Wilson's disease) must avoid GHK-Cu entirely. Active cancer patients should not use growth-promoting peptides. Pregnant or breastfeeding women lack sufficient safety data. Anyone on blood thinners should consult their physician before starting, as some peptides may influence wound healing dynamics.

Cost Breakdown

The KLOW stack is a meaningful financial commitment. Understanding the costs upfront helps you plan a realistic treatment duration. Prices vary by vendor quality and purchase quantity.

Peptide	Monthly Cost	Key Cost Factors
BPC-157	$80–$150	Purity level, quantity, vendor reputation
TB-500	$120–$250	Molecular stability, manufacturing quality
GHK-Cu	$90-$200	Copper purity, peptide stability
KPV	$60-$120	Purity, oral vs injectable form
Total Monthly	$350-$720	Source quality is the primary driver
Pre-mixed KLOW vial	$150-$300	Per 80mg vial; often more cost-effective

Higher-quality sources command premium prices, but cutting corners on peptide purity introduces contamination risk and inconsistent results. Third-party tested peptides from reputable vendors are worth the investment. Check our vendor red flags guide for sourcing tips.

Practical Administration Tips

Reconstitution

Use bacteriostatic water for all reconstitution. Store reconstituted vials in the fridge. Keep unreconstituted vials frozen. Protect everything from light.

Injection Technique

Rotate injection sites daily. Use 29-31g insulin syringes. Abdominal tissue or thigh works best. Sanitize before every injection.

Topical GHK-Cu

GHK-Cu absorbs well through skin. Combine with hyaluronic acid serum for better delivery. Apply to clean skin at 1-3% concentration. Store in opaque containers.

Frequently Asked Questions

What is the difference between KLOW and GLOW?

GLOW contains three peptides: BPC-157, TB-500, and GHK-Cu. KLOW adds a fourth compound, KPV, which is a dedicated anti-inflammatory tripeptide derived from alpha-MSH. The three compounds in GLOW handle tissue repair, structural remodeling, and collagen synthesis. KPV adds targeted NF-kB suppression and gut barrier support that the other three don't directly provide. If your recovery involves significant inflammation, gut issues, or chronic conditions, KLOW is the stronger choice. For straightforward tissue repair without a major inflammatory component, GLOW may be sufficient.

Can I take KPV orally instead of injecting it?

Yes. KPV is absorbed via the PepT1 transporter in intestinal epithelial cells, making it one of the few peptides with meaningful oral bioavailability - particularly for gut-related inflammation. Oral KPV capsules are available from some compounding pharmacies. For systemic anti-inflammatory effects beyond the gut, subcutaneous injection provides better distribution. Some users combine oral KPV (for gut support) with injected BPC-157, TB-500, and GHK-Cu.

How soon can I expect results from the KLOW stack?

Most users notice initial improvements within 7 to 14 days. Pain reduction and improved mobility come first. Full structural benefits typically develop over 4 to 6 weeks of consistent use. Complete tissue remodeling continues well beyond the active dosing period.

Does the KLOW stack work for chronic conditions?

It shows promise for chronic tendonopathies, arthritis, and lingering soft-tissue injuries. Chronic conditions often require longer treatment cycles (8 to 12 weeks). Some users benefit from maintenance dosing after the initial recovery period. Work with a healthcare provider to adjust the protocol for chronic issues.

Should I cycle these peptides?

Yes. Cycling is recommended for all four compounds. A typical approach is 8 weeks on followed by 4 to 6 weeks off. This helps maintain tissue responsiveness and reduces the chance of developing tolerance. Some protocols call for staggered cycling where you rotate individual peptides in and out.

What is the best administration method?

Subcutaneous injection is the standard for systemic effects from all four peptides. BPC-157 can also be taken orally for GI-specific issues, though absorption is less predictable. KPV has good oral bioavailability via the PepT1 transporter, especially for gut-targeted inflammation. GHK-Cu works well topically for skin and localized joint applications. See our injection guide for detailed technique instructions.

Are there drug interactions to worry about?

Peptides generally have few known drug interactions. However, GHK-Cu's copper content could theoretically interact with zinc supplementation or copper-chelating medications. Always disclose all supplements and medications to your healthcare provider before starting a peptide protocol.

Can I add other compounds to the KLOW stack?

Many users add collagen supplements, vitamin C (for collagen synthesis support), or anti-inflammatory compounds like curcumin. Some protocols include KPV peptide for additional inflammation control. Research potential interactions before adding anything, and introduce one compound at a time so you can isolate effects.

How should I store these peptides?

Reconstituted peptides go in the refrigerator and should be used within 3 to 4 weeks. Unreconstituted lyophilized powder stores best in the freezer, where it can remain stable for months. Protect all peptides from light and heat. Follow manufacturer storage instructions for specific guidance.

Is medical supervision necessary?

Strongly recommended. A healthcare provider can help determine appropriate dosing, monitor progress, identify potential interactions with existing conditions or medications, and adjust the protocol based on your specific injury and response. Self-administering peptides without medical guidance increases risk.

The Bottom Line

Summary

The KLOW stack addresses tissue repair from four distinct angles: inflammation control (KPV), vascular signaling (BPC-157), structural remodeling (TB-500), and regenerative synthesis (GHK-Cu). This four-pathway approach covers more healing mechanisms than the three-compound GLOW alternative, particularly for injuries with significant inflammation or gut involvement.

Results depend on injury severity, individual biology, and protocol adherence. The stack is not a magic bullet, but it gives damaged tissue the best biochemical environment for recovery. Proper dosing, quality sourcing, and patience during the remodeling phase all matter.

Source peptides from reputable vendors with third-party testing. Work with a knowledgeable healthcare provider. Set realistic timelines. And remember that the remodeling phase, the weeks after the pain is gone, is where the real structural repair happens.

Start Simple

Begin with the standard protocol. Adjust only after you understand how your body responds to the baseline doses.

Source Smart

Third-party COAs with HPLC and mass spec verification are non-negotiable. Read our COA guide before buying.

Stay Patient

The best outcomes come from completing the full cycle. Stopping early because symptoms improve often means incomplete tissue remodeling.

Medical Disclaimer
This article is for educational and informational purposes only. It is not medical advice and does not recommend the use of BPC-157, TB-500, GHK-Cu, or any other peptide. None of these compounds are FDA-approved for human therapeutic use. They are sold as research chemicals. Consult a qualified healthcare provider before considering any peptide regimen. Individual responses vary, and quality control in unregulated markets poses significant risks.

For compound profiles and sourcing info, visit PeptideArc.